scholarly journals Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study

BMC Cancer ◽  
2022 ◽  
Vol 22 (1) ◽  
Author(s):  
Shigemasa Takamizawa ◽  
Tatsunori Shimoi ◽  
Natsuko Satomi-Tsushita ◽  
Shu Yazaki ◽  
Toshihiro Okuya ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factor ◽  
Progression Free Survival ◽  
Recurrent Breast Cancer ◽  
Neutrophil To Lymphocyte Ratio ◽  
Cancer Center ◽  
Lymphocyte Ratio ◽  
Lymphocyte To Monocyte Ratio ◽  
Third Line ◽  
Recurrent Breast

Abstract Background Eribulin or capecitabine monotherapy is the next cytotoxic chemotherapy option for patients with metastatic or recurrent breast cancer who have previously received an anthracycline or a taxane. However, it is unclear what factors can guide the selection of eribulin or capecitabine in this setting, and prognostic factors are needed to guide appropriate treatment selection. The neutrophil-to-lymphocyte ratio (NLR) is a prognostic factor for eribulin-treated patients, although it is unclear whether it is a prognostic factor for capecitabine-treated patients. Therefore, we analysed the ability of the NLR to predict oncological outcomes among patients who received capecitabine after previous anthracycline or taxane treatment for breast cancer. Methods We retrospectively reviewed the medical records of patients with metastatic or recurrent breast cancer who had previously received anthracycline or taxane treatment at the National Cancer Center Hospital between 2007 and 2015. Patients were included if they received eribulin or capecitabine monotherapy as first-line, second-line, or third-line chemotherapy. Analyses of overall survival (OS) and progression-free survival (PFS) were performed according to various factors. Results Between 2007 and 2015, we identified 125 eligible patients, including 46 patients who received only eribulin, 34 patients who received only capecitabine, and 45 patients who received eribulin and capecitabine. The median follow-up period was 19.1 months. Among eribulin-treated patients, an NLR of <3 independently predicted better OS. Among capecitabine-treated patients, an NLR of <3 independently predicted better PFS but not better OS. In addition, a lymphocyte-to-monocyte ratio of ≥5 was associated with better PFS and OS. Conclusions To the best of our knowledge, this is the first study to evaluate whether the NLR is a prognostic factor for capecitabine-treated patients with metastatic or recurrent breast cancer. However, the NLR only independently predicted PFS in this setting, despite it being a useful prognostic factor for other chemotherapies.

Elevated neutrophil to lymphocyte ratio to predict survival outcome after recurrence for patients with triple-negative breast cancer.

2015 ◽  
Vol 33 (28_suppl) ◽  
pp. 24-24
Author(s):  
Toshiaki Iwase ◽  
Takafumi Sangai ◽  
Masahiro Sakakibara ◽  
Takeshi Nagashima ◽  
Masaru Miyazaki
Keyword(s):  
Breast Cancer ◽  
Chronic Inflammation ◽  
Triple Negative ◽  
Recurrent Breast Cancer ◽  
Neutrophil To Lymphocyte Ratio ◽  
World Health ◽  
Skeletal Muscle Index ◽  
Lymphocyte Ratio ◽  
Recurrent Breast ◽  
The Impact

24 Background: Recent studies show that obesity plays a major role in causing chronic inflammation by producing several inflammatory cytokines. On the other hand, there is limited research focusing on the effect of obesity in recurrent breast cancer treatments. Therefore, we set out to clarify the impact of obesity related inflammation by Neutrophil to Lymphocyte ratio (N/L ratio) in recurrent breast cancer treatment. Methods: From January 2005 to December 2014, 93 patients with recurrent breast cancer after surgery were included. World Health Organization body mass index (BMI) classification was used for evaluating the degree of obesity. Muscle mass amount was also analyzed. Lumber skeletal muscle index (LSMI, cm2/m2) was generated by standardizing each patient’s muscle area (m2) at the third lumber vertebrae level in axial CT data. Less than 50m2 in LSMI was defined as pre-sarcopenia. N/L ratio was calculated from the laboratory data, and more than 3.0 was defined as high N/L group. Results: Patient background showed there were 20 overweight patients and 2 obese patients. Twenty-eight cases had pre-sarcopenia. In univariate analysis, N/L ratio had no significant differences among BMI categories. However, triple negative (TN) type demonstrated significantly high N/L ratio compared to other subtypes (p < 0.05). LMSI had significant negative correlation to N/L ratio (p < 0.05). In survival analysis, Overweight/Obese group showed significantly shorter OS (p < 0.05). High N/L ratio group also showed similar results (p < 0.05). When stratified by intrinsic subtypes, TN type demonstrated significantly shorter OS (p < 0.05). Additionally, Overweight/Obese groups in TN type had notably shorter OS (p < 0.05). In multivariate analysis, subtype and N/L ratio were independently related to OS (Hazard ratio: 3.3 in TN type, 2.9 in High NL ratio group). Conclusions: Present study did not show any significant relationship between obesity and chronic inflammation in recurrent breast cancer setting. On the contrary, intrinsic subtype was significantly related to inflammation, leading to pre-sarcopenia and worse OS. Whether obesity promotes inflammation in TN type needs more investigation.

Phase III Study of N,N-Diethyl-2-[4-(Phenylmethyl) Phenoxy]Ethanamine (BMS-217380-01) Combined With Doxorubicin Versus Doxorubicin Alone in Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19

2004 ◽  
Vol 22 (2) ◽  
pp. 269-276 ◽  
Author(s):  
Leonard Reyno ◽  
Lesley Seymour ◽  
Dongsheng Tu ◽  
Susan Dent ◽  
Karen Gelmon ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast ◽  
Progression Free Survival ◽  
Recurrent Breast Cancer ◽  
Phase Iii ◽  
Metastatic Breast Carcinoma ◽  
Significant Difference ◽  
Recurrent Breast

Purpose N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine (DPPE; tesmilifene) is a novel agent that augments chemotherapy cytotoxicity in vitro and in vivo. A phase II trial combining DPPE and doxorubicin (DOX) in metastatic breast carcinoma showed increased response over that expected with DOX. We report a phase III trial comparing DOX with DPPE plus DOX in metastatic or recurrent breast cancer. Patients and Methods Anthracycline-naive women with measurable metastatic disease were randomly assigned to receive, every 21 days, either DOX 60 mg/m2 intravenously or DOX during the last 20 minutes of an 80-minute infusion of DPPE (5.3 mg/kg), in both cases to cumulative DOX doses of 450 mg/m2. Patients receiving DPPE were aggressively premedicated to ameliorate toxicity. End points included progression-free survival (PFS), response rate (RR), and response duration (RD), quality of life (QOL), toxicity, and overall survival (OS). Results A planned interim analysis failed to detect an RR difference more than 5%. The study was closed to additional accrual and all DPPE was discontinued. The final analysis was conducted as planned after 256 progression events (median follow-up, 20.5 months). There was no significant difference in RR, RD, or PFS between arms. DPPE plus DOX was statistically superior to DOX in OS (hazard ratio, 0.66; 95% CI, 0.48 to 0.91; P = .021). DPPE plus DOX was associated with more gastrointestinal and CNS toxicity. No consistent influence on QOL was detected. Conclusion This study demonstrated no advantage in RR, RD, or PFS but significantly superior OS for DPPE plus DOX. Additional studies of DPPE are warranted.

scholarly journals Radiotherapy-Induced High Neutrophil-to-Lymphocyte Ratio is a Negative Prognostic Factor in Patients with Breast Cancer

Cancers ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 1896
Author(s):  
Chang Ik Yoon ◽  
Dooreh Kim ◽  
Sung Gwe Ahn ◽  
Soong June Bae ◽  
Chihwan Cha ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factor ◽  
Cancer Patients ◽  
Tumor Recurrence ◽  
Neutrophil To Lymphocyte Ratio ◽  
Significant Prognostic Factor ◽  
Prognostic Impact ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Lymphocyte Ratio

Radiotherapy (RT) is the standard of care following breast-conserving operation in breast cancer patients. The neutrophil-to-lymphocyte ratio (NLR) reflects the systemic change caused as a result of the radiotherapy. We aimed to evaluate the association between RT and the change in NLR following the receipt of RT, and to investigate the prognostic impact. We retrospectively reviewed NLR values of breast cancer patients taken before the administration of the first and the last session of RT. The cut-off point for the NLR was determined using the Youden index and receiver operating characteristic (ROC) curve within the training set. Recurrence-free survival (RFS), distant metastasis free survival, and overall survival were the main outcomes. Patients with an NLR higher than 3.49 after RT were classified to an RT-induced high NLR group and showed a significantly higher recurrence rate compared to those with low NLR (p < 0.001). In a multivariate Cox proportional hazards model, RT-induced high NLR remained a significant prognostic factor (HR 2.194, 95% CI 1.230–3.912, p = 0.008 for tumor recurrence. We demonstrated that an increase in NLR over the course of RT has a negative impact on survival, putting these patients with RT-susceptible host immunity at a higher risk of tumor recurrence.

Sign in / Sign up

Export Citation Format

Share Document